SER
Serina Therapeutics, Inc.Company with tickers: SER
CIK
1708599
CUSIP
81751A108
Shares Outstanding
14,997,505
13F Activity (30d)
23 filings
21 filers
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | — | ||||
| Revenue (ASC 606) | — | ||||
| Cost of Revenue | — | ||||
| Gross Profit | — | ||||
| Operating Expenses | $6,280,000 | USD | 2026-03-31 | 10-Q | 2026-05-14 |
| Research & Development | $3,199,000 | USD | 2026-03-31 | 10-Q | 2026-05-14 |
| Operating Income | — | ||||
| Net Income | $-6,898,000 | USD | 2026-03-31 | 10-Q | 2026-05-14 |
| EPS (Basic) | $-0.58 | USD/shares | 2026-03-31 | 10-Q | 2026-05-14 |
| EPS (Diluted) | $-0.58 | USD/shares | 2026-03-31 | 10-Q | 2026-05-14 |